Cipla is currently trading at Rs. 432.50, up by 3.65 points or 0.85% from its previous closing of Rs. 428.85 on the BSE.
The scrip opened at Rs. 432.25 and has touched a high and low of Rs. 435.00 and Rs. 430.45 respectively. So far 170697 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 435.00 on 09-Jan-2013 and a 52 week low of Rs. 286.50 on 26-Mar-2012.
Last one week high and low of the scrip stood at Rs. 431.70 and Rs. 414.00 respectively. The current market cap of the company is Rs. 34706.28 crore.
The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 34.15% and 28.75% respectively.
State-run Life Insurance Corporation of India (LIC) has offloaded 1.7 crore shares representing 2.12% stake of in drug manufacturer Cipla through open market transactions between August 21, 2012 and January 7, 2013. Following this, the insurer’s stake in Cipla reduced to 6.21% from 8.34%.
Meanwhile, Foreign Institutional Investors (FIIs) have raised their holding in Cipla to 20.79% in September 2012 from 13.09% at the end of December 2011.
Cipla focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: